Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19).
作者信息
Shang You, Wu Jianfeng, Liu Jinglun, Long Yun, Xie Jianfeng, Zhang Dong, Hu Bo, Zong Yuan, Liao Xuelian, Shang Xiuling, Ding Renyu, Kang Kai, Liu Jiao, Pan Aijun, Xu Yonghao, Wang Changsong, Xu Qianghong, Zhang Xijing, Zhang Jicheng, Liu Ling, Zhang Jiancheng, Yang Yi, Yu Kaijiang, Guan Xiangdong, Chen Dechang
机构信息
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510010, China.
出版信息
J Intensive Med. 2022 Aug 26;2(4):199-222. doi: 10.1016/j.jointm.2022.07.001. eCollection 2022 Oct.
Abstract
摘要
相似文献
1
Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19).
J Intensive Med. 2022 Aug 26;2(4):199-222. doi: 10.1016/j.jointm.2022.07.001. eCollection 2022 Oct.
2
[Chinese experts' consensus on diagnosis and treatment of severe and critical coronavirus disease 2019 (revised edition)].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Mar;32(3):269-274. doi: 10.3760/cma.j.cn121430-20200218-00188.
3
[Experts consensus for the diagnosis, treatment, and prevention of coronavirus disease 2019 in the elderly].
Zhonghua Nei Ke Za Zhi. 2020 Aug 1;59(8):588-597. doi: 10.3760/cma.j.cn112138-20200228-00151.
4
Updated diagnosis, treatment and prevention of COVID-19 in children: experts' consensus statement (condensed version of the second edition).
World J Pediatr. 2020 Jun;16(3):232-239. doi: 10.1007/s12519-020-00362-4. Epub 2020 Apr 24.
5
[Discussion and suggestion on the classification of severe and critical coronavirus disease 2019 in Chinese experts' consensus on diagnosis and treatment of severe and critical coronavirus disease 2019].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Mar;32(3):277. doi: 10.3760/cma.j.cn121430-20200226-00339.
6
Expert consensus on the procedure of interventional diagnosis and treatment of cancer patients during the COVID-19 epidemic.
J Interv Med. 2020 May;3(2):61-64. doi: 10.1016/j.jimed.2020.03.001. Epub 2020 Mar 31.
7
Imaging examination, diagnosis, and control and prevention of nosocomial infection for coronavirus disease 2019: Expert consensus of Hunan radiologist.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Mar 28;45(3):221-228. doi: 10.11817/j.issn.1672-7347.2020.200081.
8
Holistic care for patients with severe coronavirus disease 2019: An expert consensus.
Int J Nurs Sci. 2020 Apr 4;7(2):128-134. doi: 10.1016/j.ijnss.2020.03.010. eCollection 2020 Apr 10.
9
An overview of the expert consensus on the mental health treatment and services for major psychiatric disorders during COVID-19 outbreak: China's experiences.
Int J Biol Sci. 2020 May 25;16(13):2265-2270. doi: 10.7150/ijbs.47419. eCollection 2020.
10
[Expert consensus on treatment of severe COVID-19 caused by Omicron variants].
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Feb 12;46(2):101-110. doi: 10.3760/cma.j.cn112147-20221230-00994.
引用本文的文献
1
Herbal and Dietary Supplements as Adjunctive Treatment for Mild SARS-CoV-2 Infection in Italy.
Nutrients. 2025 Jan 9;17(2):230. doi: 10.3390/nu17020230.
2
Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial.
BMC Pharmacol Toxicol. 2023 Jun 15;24(1):38. doi: 10.1186/s40360-023-00678-7.
本文引用的文献
1
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.
Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443.
2
Laboratory Diagnosis for SARS-CoV-2 Infection.
Infect Dis Clin North Am. 2022 Jun;36(2):327-347. doi: 10.1016/j.idc.2022.02.002.
3
A Short Series of Case Reports of COVID-19 in Immunocompromised Patients.
Viruses. 2022 Apr 29;14(5):934. doi: 10.3390/v14050934.
4
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Clin Pharmacol Ther. 2022 Dec;112(6):1191-1200. doi: 10.1002/cpt.2646. Epub 2022 Jun 7.
5
Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?
Int J Environ Res Public Health. 2022 Apr 11;19(8):4586. doi: 10.3390/ijerph19084586.
6
Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants - China, May 21, 2021-February 28, 2022.
China CDC Wkly. 2022 Apr 8;4(14):293-297. doi: 10.46234/ccdcw2022.074.
7
SARS-CoV-2 pathogenesis.
Nat Rev Microbiol. 2022 May;20(5):270-284. doi: 10.1038/s41579-022-00713-0. Epub 2022 Mar 30.
8
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022.
MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):459-465. doi: 10.15585/mmwr.mm7112e1.
9
Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments : A Retrospective Cohort Study.
Ann Intern Med. 2022 Jun;175(6):831-837. doi: 10.7326/M22-0308. Epub 2022 Mar 15.
10
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.
BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
Zotero 插件